Article
RSV604, a novel inhibitor of respiratory syncytial virus replication.
Antimicrobial agents and chemotherapy - 1 Sept 2007
Chapman Joanna, Abbott Elizabeth, Alber Dagmar G, Baxter Robert C, Bithell Sian K, Henderson Elisa A, Carter Malcolm C, Chambers Phil, Chubb Ann, Cockerill G Stuart, Collins Peter L, Dowdell Verity C L, Keegan Sally J, Kelsey Richard D, Lockyer Michael J, Luongo Cindy, Najarro Pilar, Pickles Raymond J, Simmonds Mark, Taylor Debbie, Tyms Stan, Wilson Lara J, Powell Kenneth L
Abstract excerpt
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections worldwide, yet no effective vaccine or antiviral treatment is available. Here we report the discovery and initial development of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity. It proved to be equipotent against all clinical isolates tested of both the A and B subtypes of the virus. The compound...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.